Enhanced activity of apramycin and apramycin-based combinations against Mycobacteroides abscessus.

ABSTRACT:

Background

Mycobacteroides abscessus is a rapidly growing non-tuberculous mycobacterium that causes chronic lung and soft tissue infections. Treatment options are severely limited. Amikacin has historically been a mainstay of combination treatment regimens. However, irreversible hearing loss and vestibular toxicity have led to a search for alternative agents. Apramycin is a novel aminoglycoside currently in Phase I clinical trials that may offer lower potential for ototoxic and renal toxic side effects.

Objectives

The goal of this study was to compare apramycin's in vitro activity with amikacin and other aminoglycosides against a large collection of M. abscessus clinical isolates, alone, and for apramycin and amikacin, in combination with clofazimine or linezolid. We also ex

SUBMITTER: Huang Y 

PROVIDER: S-EPMC12802941 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature